At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,161 enrolled
Drug / intervention
LCZ696 +2 moredrug
Likely dose
LCZ696 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating LCZ696, Olmesartan, and 1 other intervention for Essential Hypertension. Completed, enrolled 1,161 participants across 61 sites.
Detailed Summary
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJun 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedMay 15, 2012
Enrollment StartJun 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.1 years ago
Interventions
LCZ696drug
200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
Olmesartandrug
Olmesartan 20 mg capsule one daily
Placebodrug
Placebo to LCZ696 or Olmesartan